1 | increasing | 21,734 |
2 | expanding | 648 |
3 | advancing | 625 |
4 | ever-increasing | 71 |
5 | ever-growing | 15 |
6 | inter-dental | 7 |
7 | equitoxic | 6 |
8 | extensional | 6 |
9 | angling | 4 |
10 | ever-widening | 4 |
11 | glancing | 4 |
12 | insusceptibility | 4 |
13 | tipburn | 4 |
14 | honours | 3 |
15 | heavy-headed | 2 |
16 | incrementing | 2 |
17 | ptl.in | 2 |
18 | recessing | 2 |
19 | thermalize | 2 |
20 | 'uneasy | 1 |
21 | 1,4-dibromobenzene | 1 |
22 | 1.69-times | 1 |
23 | 1hnmr-spectroscopy | 1 |
24 | 2.55-times | 1 |
25 | 5-chloro-3-methyl-1-phenyl-1h-pyrazole-4-carbaldehyde | 1 |
26 | 500-600mg/day | 1 |
27 | a-posteriori | 1 |
28 | cs40-o-t | 1 |
29 | ear-mark | 1 |
30 | end-of-class | 1 |
31 | endosinus | 1 |
32 | gp/practice | 1 |
33 | gritty/sandy | 1 |
34 | haemogamasus | 1 |
35 | knowing-visual | 1 |
36 | landsat-derived | 1 |
37 | late-childhood-onset | 1 |
38 | lbp.in | 1 |
39 | light-headed | 1 |
40 | maintained-high | 1 |
41 | median-split | 1 |
42 | midocclusions | 1 |
43 | peers.on | 1 |
44 | placebo.where | 1 |
45 | pyonephrosis-in | 1 |
46 | submillimolar | 1 |
47 | thosebefore | 1 |
48 | valgancicloviras | 1 |
1 | 'uneasy | 1 |
2 | 1,4-dibromobenzene | 1 |
3 | 1.69-times | 1 |
4 | 1hnmr-spectroscopy | 1 |
5 | 2.55-times | 1 |
6 | 5-chloro-3-methyl-1-phenyl-1h-pyrazole-4-carbaldehyde | 1 |
7 | 500-600mg/day | 1 |
8 | a-posteriori | 1 |
9 | advancing | 625 |
10 | angling | 4 |
11 | cs40-o-t | 1 |
12 | ear-mark | 1 |
13 | end-of-class | 1 |
14 | endosinus | 1 |
15 | equitoxic | 6 |
16 | ever-growing | 15 |
17 | ever-increasing | 71 |
18 | ever-widening | 4 |
19 | expanding | 648 |
20 | extensional | 6 |
21 | glancing | 4 |
22 | gp/practice | 1 |
23 | gritty/sandy | 1 |
24 | haemogamasus | 1 |
25 | heavy-headed | 2 |
26 | honours | 3 |
27 | increasing | 21,734 |
28 | incrementing | 2 |
29 | insusceptibility | 4 |
30 | inter-dental | 7 |
31 | knowing-visual | 1 |
32 | landsat-derived | 1 |
33 | late-childhood-onset | 1 |
34 | lbp.in | 1 |
35 | light-headed | 1 |
36 | maintained-high | 1 |
37 | median-split | 1 |
38 | midocclusions | 1 |
39 | peers.on | 1 |
40 | placebo.where | 1 |
41 | ptl.in | 2 |
42 | pyonephrosis-in | 1 |
43 | recessing | 2 |
44 | submillimolar | 1 |
45 | thermalize | 2 |
46 | thosebefore | 1 |
47 | tipburn | 4 |
48 | valgancicloviras | 1 |
1 | equitoxic | 6 |
2 | light-headed | 1 |
3 | heavy-headed | 2 |
4 | landsat-derived | 1 |
5 | gp/practice | 1 |
6 | 5-chloro-3-methyl-1-phenyl-1h-pyrazole-4-carbaldehyde | 1 |
7 | 1,4-dibromobenzene | 1 |
8 | placebo.where | 1 |
9 | thosebefore | 1 |
10 | thermalize | 2 |
11 | glancing | 4 |
12 | advancing | 625 |
13 | expanding | 648 |
14 | angling | 4 |
15 | ever-widening | 4 |
16 | increasing | 21,734 |
17 | ever-increasing | 71 |
18 | recessing | 2 |
19 | incrementing | 2 |
20 | ever-growing | 15 |
21 | maintained-high | 1 |
22 | a-posteriori | 1 |
23 | ear-mark | 1 |
24 | extensional | 6 |
25 | inter-dental | 7 |
26 | knowing-visual | 1 |
27 | pyonephrosis-in | 1 |
28 | ptl.in | 2 |
29 | lbp.in | 1 |
30 | peers.on | 1 |
31 | tipburn | 4 |
32 | submillimolar | 1 |
33 | valgancicloviras | 1 |
34 | 2.55-times | 1 |
35 | 1.69-times | 1 |
36 | midocclusions | 1 |
37 | honours | 3 |
38 | end-of-class | 1 |
39 | endosinus | 1 |
40 | haemogamasus | 1 |
41 | cs40-o-t | 1 |
42 | late-childhood-onset | 1 |
43 | median-split | 1 |
44 | 500-600mg/day | 1 |
45 | gritty/sandy | 1 |
46 | 1hnmr-spectroscopy | 1 |
47 | 'uneasy | 1 |
48 | insusceptibility | 4 |